{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349154","form_type":"8-K","ticker":"EIKN","cik":"0001861123","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-08-13T20:06:11+00:00","discovered_at":"2026-08-13T20:09:04.456747+00:00","generated_at":"2026-08-13T20:09:59.364853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eikon Q2 2026 net loss $88.4M, cash $531.2M; EIK1001 DMC selects dose","bullets":["Net loss $88.4M vs $105.2M prior year; R&D $75.5M (+9%), G&A $17.9M (-56%).","Cash $531.2M at June 30, 2026; expected to fund operations into H2 2027.","EIK1001 TeLuRide-006 DMC selected single dosing regimen; TeLuRide-008 first patient dosed.","Seven abstracts accepted at ESMO 2026; initial EIK1004 and EIK1005 data to be presented.","Appointed Ma. Fatima Francisco to Board; EIK1006 IND expected by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349154","json":"https://secwatch.observer/filing/0001193125-26-349154.json","markdown":"https://secwatch.observer/filing/0001193125-26-349154.md","text":"https://secwatch.observer/filing/0001193125-26-349154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/0001193125-26-349154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/eikn-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:09:59.364853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}